Butyrolactone 3, also called MB-3 is an inhibitor of Histone acetyltransferase GCN5 (general control of amino-acid synthesis 5). Gcn5 HAT activity is required to acetylate histone H3 lysine 9 (K9) and K14, which allows transcription elongation by relaxing nucleosomes. Butyrolactone 3 specifically inhibits Gcn5's HAT activity. It has been shown to display anti-inflammatory and anti-carcinogenic effects.
1. Mai, Antonello., et al., 2006. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. Journal of medicinal chemistry. 49(23): 6897-907. PMID: 17154519
2. Holmlund, T., et al., 2013. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia. 27(3): 578-85. PMID: 23044487
See how others have used Butyrolactone 3. Click on the entry to view the PubMed entry .
PMID: # 29235036 Ho, CF.|Bon, CP.|Ng, YK.|Herr, DR.|Wu, JS.|Lin, TN.|Ong, WY.| et al. 2018. Neurochem. Res. 43: 540-555.
PMID: # 26162318 Tan, CS. et al. 2015. Molecular neurobiology.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.